CCR5 antagonists for the treatment of HIV.
The CCR5 chemokine receptor is expressed on a wide range of immune cell types and binding to this receptor mediates cellular entry by the majority of HIV isolates. Blocking viral entry via this receptor reduces the viral load in patients infected with HIV, suggesting that a CCR5 antagonist could become a key component in the treatment of HIV-compromised patients. A number of CCR5 antagonists are currently in clinical trials. This review details the status of leading agents and highlights recent advances in the development of new CCR5 antagonists.
Barber
Chris G
CG
Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK. christopher_barber@sandwich.pfizer.com
D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D065100:CCR5 Receptor Antagonists; D004345:Drug Industry; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists